Abbott Receives Positive Opinion from CHMP for HUMIRA

Abbott Receives Positive Opinion from CHMP for HUMIRA Use in Pediatric
Benzinga
(NYSE) today announced that the () has adopted a positive opinion for ® (adalimumab) for the treatment of patients aged six to 17 years with severely active Crohn’s disease (CD) who failed, are intolerant to or have contraindications to conventional therapy. Following the ’s positive opinion, a final decision from the European Commission is anticipated in the next several weeks. Upon final decision, HUMIRA will be the only biologic in the (EU) for the treatment of pediatric CD offering at-home administration.Pediatric CD is a chronic, debilitating condition of the (GI) tract that affects up to 200,000 children worldwide(i,ii) CD most commonly involves the end of the small intestine and the beginning of the .(iii) In addition to symptoms such as , weight loss and (i) pediatric CD can affect children in several ways, including potentially contributing to malnutrition, failure to grow and/or .(i,iv)(c) 2012 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Maximize your portfolio – Download the “5 Emerging Markets ETFs: Financial Power For The 21st Century” eBook by Benzinga’s ETF Professor HERE.

Read more: http://www.benzinga.com/news/12/10/3009829/abbott-receives-positive-opinion-from-chmp-for-humira-use-in-pediatric-crohns-dis#ixzz29ojseGuC (CD)

 

Leave a Reply